8.09
+0.47(+6.17%)
Currency In USD
| Previous Close | 7.62 |
| Open | 7.59 |
| Day High | 8.13 |
| Day Low | 7.57 |
| 52-Week High | 8.88 |
| 52-Week Low | 4.03 |
| Volume | 2.29M |
| Average Volume | 2.12M |
| Market Cap | 1.68B |
| PE | -13.71 |
| EPS | -0.59 |
| Moving Average 50 Days | 7.61 |
| Moving Average 200 Days | 7.12 |
| Change | 0.47 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $762.49 as of February 05, 2025 at a share price of $8.09. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $2,661.18 as of February 05, 2025 at a share price of $8.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
GlobeNewswire Inc.
Jan 10, 2025 12:00 PM GMT
—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in 2024 (not including stock-based compensation) and exp
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 07, 2025 12:00 PM GMT
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
GlobeNewswire Inc.
Nov 18, 2024 7:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO® (berotralstat) for the routine prevention of